☰

Affibody AB

From platform discovery to integrated biopharma

Industry
Clinical-stage biopharmaceuticals (radiopharmaceuticals and immunology)
Headquarters
Solna, Stockholm, Sweden
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Affibody AB's published strategy and is not endorsed by, or produced in cooperation with, Affibody AB. Company website

Strategic priorities

Affibody AB is a Swedish clinical-stage biopharmaceutical company built on its Affibody® protein-engineering platform. The 2024 Annual Report records R&D expense at 72.4 percent of operating expenses and a workforce anchored at Solna, with R&D sites co-located in the Stockholm-Uppsala life-science corridor and clinical operations extending into Germany for the ABY-271 radiopharmaceutical program.

The company announced in January 2025 that it had regained the Asian rights to izokibep from Inmagene, and in February 2025 the global rights from ACELYRIN. The transition to integrated biopharma now runs on a three-month asset-transfer window during which Affibody must absorb large, differently-structured clinical datasets and stand up the internal GxP and regulatory infrastructure to take izokibep forward.

In parallel, the ABY-271 radiopharmaceutical trial was cleared by the Trial Review Committee to escalate into Part B with higher radioactivity doses, drawing on dosimetry data drawn from nuclear-medicine imaging, clinical reports and biodistribution software. Lutetium-177 has a half-life of 6.7 days, so production, quality control and patient administration all sit inside a narrow coordination window. Patricia Industries, a division of Investor AB, is the long-term shareholder.

All three workstreams — clinical data inheritance, radiopharmaceutical escalation and the move from outsourced to internal infrastructure — point to the same underlying capability: data that can be queried and signed-off across partner estates, laboratory systems, and regulatory submissions without manual reconciliation.

Challenges we see

  • Digital Integration

    Absorbing inherited clinical datasets within the transfer window

    Affibody regained the global rights to izokibep from ACELYRIN in February 2025 and the Asian rights from Inmagene in January 2025, with a three-month asset-transfer window. The 2024 Annual Report and a January 2025 press release describe the inheritance as large clinical datasets held under different data standards and ontologies.

    Where clinical evidence lives in two separately-shaped partner estates, queries written against one set will not return comparable answers from the other. Treating the combined izokibep record as one queryable evidence base is a precondition for the regulatory work that follows.

  • Operations Manufacturing

    Coordinating short-half-life radiopharmaceutical doses across sites

    The ABY-271 program uses Lutetium-177, which has a 6.7-day half-life. Production, quality control and patient administration are described in Affibody's clinical protocol as having to occur within a narrow window, with manufacturing outsourced to specialised contract development and manufacturing organisations (CDMOs) and clinical activity running in Sweden and Germany.

    Where the dose's useful life is shorter than the planning cycle, a delay at any handoff reduces the dose below its clinical target. Predictive scheduling, condition monitoring and a shared coordination view compresses the time between decision and patient.

  • Digital Operations

    Closing the laboratory digital gap in Solna R&D

    Affibody manages a discovery library of more than 10 billion molecules from its Solna research base. The research file describes data collection in the Solna labs as largely manual or paper-based, with bioreactors, chromatography systems and balances lacking OPC UA (Open Platform Communications Unified Architecture) or MQTT (Message Queuing Telemetry Transport) interoperability.

    Where instruments speak different protocols or only log to paper, the time between an experiment and a queryable result runs in days rather than minutes. Standardising the lab's connectivity puts the discovery operation on the same data turnaround the rest of the business now requires.

  • Compliance Regulatory

    Reconciling dosimetry and biodistribution data for radiopharmaceutical trials

    The ABY-271 trial protocol requires granular dosimetry and biodistribution data for the Trial Review Committee, drawn from nuclear-medicine imaging, clinical reports and dosimetry software. The Trial Review Committee has approved escalation into Part B with higher radioactivity doses.

    Where imaging, clinical and dosimetry evidence must agree before each phase decision, reconciliation time sits directly in the regulatory path. Automating the aggregation moves the bottleneck from manual comparison to clinical interpretation.

  • Digital Integration

    Securing expanding clinical and laboratory data flows

    Affibody's global footprint is widening with ABY-271 sites in Sweden and Germany, alongside the inherited izokibep data and increased collaboration with external clinical sites. The research file references air-gapped legacy equipment in research settings as creating both access and security constraints.

    Where new clinical sites and partner datasets multiply the touch points on sensitive data, the security model has to be specified per connection rather than assumed from the network boundary.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Loading inherited clinical datasets against one evidence model

    Izokibep's clinical record is being inherited from ACELYRIN and Inmagene under different data standards and ontologies. The 2024 Annual Report and the January 2025 press release describe the inherited datasets as fragmented across silos.

    An agreed ontology for trial, subject, visit, assay and result lets both estates load against one model, so cross-study analysis and regulatory submissions query a single source of truth rather than reconciling per report.

    • Affibody regains worldwide rights to izokibep, press release, 2025
    • Affibody Annual Report 2024

  2. Bringing OPC UA and MQTT connectivity into the Solna discovery lab

    Affibody manages a library of more than 10 billion molecules from Solna while much of the data collection remains manual or paper-based, and the research file describes bioreactors, chromatography systems and balances as lacking standard interoperability.

    Connecting instruments through OPC UA and MQTT turns the existing lab equipment into a continuously updating data source, with dashboards showing running experiments against historical baselines rather than reconstructed after the fact.

    • Affibody deep research file, section 2
    • Affibody Annual Report 2024

  3. Coordinating Lu-177 logistics with a shared timeline

    Lutetium-177's 6.7-day half-life forces production, quality control and patient administration into a narrow window, with manufacturing outsourced to specialised CDMOs and clinical activity running in Sweden and Germany.

    A coordination view across production release, QC sign-off, transit and patient scheduling, with exception alerts raised before a dose becomes clinically unusable, lets the program hold dose availability above its current planning margin.

    • Affibody Accelerates Phase 1 Study with ABY-271, press release, 2025
    • ABY-271 Clinical Protocol

  4. Aggregating dosimetry evidence for Trial Review Committee submissions

    ABY-271 submissions require granular dosimetry and biodistribution data from nuclear-medicine imaging, clinical reports and dosimetry software. The Trial Review Committee has now approved escalation to Part B with higher radioactivity doses.

    Pipelines that aggregate imaging, clinical and biodistribution records into a single dossier with their lineage intact shorten the time between a Trial Review Committee submission and a phase decision, and make the evidence chain inspectable on demand.

    • Affibody's ABY-271 breast cancer trial cleared to progress to next phase, 2025
    • Affibody Accelerates Phase 1 Study with ABY-271, press release, 2025

  5. Securing cross-site data flows while keeping research data reachable

    Affibody's clinical and laboratory footprint is widening with ABY-271 sites in Sweden and Germany and increased external collaboration. The research file describes air-gapped legacy equipment in research settings as a constraint on both access and security.

    A zero-trust connectivity model that brokers access to legacy and modern systems per identity and per request lets research data reach the people who need it while keeping the network posture auditable to IEC 62443, the international standard for industrial automation cybersecurity.

    • Affibody deep research file, section 2
    • Affibody Annual Report 2024

What we'd propose

  • Enterprise AI

    One evidence model for the inherited izokibep datasets

    An ontology-driven data platform that defines the entities both partner estates share — trial, subject, visit, assay, result, site — once, then loads the ACELYRIN and Inmagene contributions against that single model.

    • Shared clinical evidence ontology

      One agreed set of terms

      Define trial, subject, visit, assay, result, site and lot as explicit entities with agreed relationships, so a regulatory query written once returns comparable answers from both partner estates instead of two dialects of the same table.

    • Ingestion from ACELYRIN and Inmagene estates

      Loading both sides

      Build connectors for the ACELYRIN and Inmagene source systems with schema validation at the boundary so that records that do not match the model fail loudly rather than silently corrupting downstream analyses.

    • Submission-ready analytics and retrieval

      Questions answered without IT tickets

      Expose the model through dashboards and a retrieval layer so regulatory, clinical and medical-affairs teams can query the combined evidence base directly, with lineage back to the source partner for every answer.

    • Inheritance becomes a single load against an agreed model, not a per-report reconciliation.
    • Cross-study analysis returns results that are internally consistent and lineage-traceable.
    • Future partner or acquisition datasets attach to the model rather than triggering a new migration.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    OPC UA and MQTT connectivity across the Solna discovery lab

    An instrument-connectivity programme for the Solna labs, bringing bioreactors, chromatography systems and balances onto OPC UA or MQTT and surfacing the data into shared, queryable dashboards.

    • Instrument connectivity layer

      Getting data off the equipment

      Connect each instrument through OPC UA or MQTT so process values leave the equipment in a documented, vendor-neutral form rather than staying inside a closed controller or on a paper log.

    • Real-time KPI dashboards

      Live process visibility

      Build dashboards that show running experiments against historical baselines (golden-batch comparison), with calculated biological metrics alongside physical sensor data so scientists see the same view of the experiment the equipment has.

    • Paperless lab workflows

      Records captured at source

      Replace paper notebooks and manual transcription with digital capture directly from instruments, with electronic signatures and audit trails to 21 CFR Part 11, the US rule on electronic records and signatures.

    • Time between experiment and queryable result moves from days to minutes.
    • Manual data collection, estimated at up to 65 percent of scientist time in the research file, is replaced by instrument capture.
    • Discovery data is produced once with provenance, not reconstructed for every report.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Radiopharmaceutical coordination view across CDMOs and clinical sites

    A shared timeline and exception-monitoring platform for ABY-271 Lu-177 doses, connecting production release at the contract manufacturer, quality control, transit and patient administration at the clinical site in Sweden or Germany.

    • Production and QC status feed

      Live dose readiness

      Ingest release and quality-control status from the contract manufacturer so the program team sees when a dose is ready, on hold or rejected, without phone calls and emails.

    • Cold chain and condition monitoring

      Tracking the dose in transit

      Connect shipment-condition sensors through the logistics chain with exception alerts raised before the dose loses clinical usefulness.

    • Coordination dashboard

      One shared timeline

      Provide a single view of dose readiness, transit, clinic scheduling and patient slot, with predictive flags raised when a planned slot is at risk of missing the Lu-177 half-life window.

    • Dose availability is visible across the program rather than reconstructed per shipment.
    • Exceptions surface while there is still time to re-route or re-time the dose.
    • Chain-of-custody evidence is generated as the dose moves, not compiled for an audit.

    We've done this before

    See how we do Enterprise AI
  • Enterprise AI

    Automated dosimetry pipeline for Trial Review Committee submissions

    An aggregation pipeline that pulls imaging, clinical and biodistribution records into a single Trial Review Committee dossier with lineage back to the source systems.

    • Imaging and clinical ingestion

      Loading both source types

      Ingest nuclear-medicine imaging output and the clinical and biodistribution records produced alongside it, with schema validation at the boundary so every record in the dossier can be traced back to its source.

    • Biodistribution and dosimetry modelling

      Computation as data

      Run dosimetry and biodistribution calculations against the ingested records, persisting the calculations as data with their inputs attached so the Trial Review Committee can interrogate any result.

    • Submission dossier assembly

      Dossiers built from lineage

      Assemble the Trial Review Committee dossier directly from the modelled results, with the source records retrievable from the dossier itself rather than reconstructed for each submission.

    • Time between data generation and Trial Review Committee submission shortens.
    • Every result in the dossier carries an inspectable lineage back to source.
    • Phase-escalation decisions rest on a reproducible evidence base rather than a per-submission assembly.

    We've done this before

    See how we do Enterprise AI
  • Agents

    AI agents for clinical and regulatory document work

    Narrow, reviewable agents that take the repetitive part of regulatory document work at Affibody: drafting Trial Review Committee submission summaries from modelled dosimetry outputs, checking a document against its template before review, and finding every controlled document that an izokibep rights transfer or standards change touches. A named person approves every output.

    • Drafting from modelled clinical records

      First drafts from system data

      Generate the first draft of a Trial Review Committee summary, a periodic safety report or an izokibep-related regulatory document directly from the underlying modelled records, so the author edits and judges rather than assembles.

    • Template and completeness checking

      Gaps found before review

      Check a submitted document against its regulatory template and Affibody's own checklist, returning missing or inconsistent sections before it enters the review queue.

    • Change-impact search across the document set

      Which documents a change touches

      When an izokibep rights transfer, a Trial Review Committee decision or a standards change occurs, retrieve every controlled document that references it and rank them by how directly they are affected, so the update scope is known on day one.

    • Review queues move faster because documents arrive complete and traceable.
    • The scope of a regulatory or transfer change is established by search rather than by recollection.
    • Every output is signed off by a named reviewer and traceable to the source records it came from.

    We've done this before

    See how we do Agents

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Affibody AB's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data integration 28 → 80
Inherited clinical datasets sit in two partner estates under different ontologies, and laboratory data remains captured manually in Solna. Unifying these into one queryable evidence base is work that runs ahead of the company rather than behind it.
Lab automation 32 → 78
Solna R&D relies on paper notebooks and disconnected instruments; OPC UA and MQTT adoption is described as limited in the research file. The platform's 10-billion-molecule library sits on top of workflows that are still largely manual.
Supply chain visibility 22 → 72
Lu-177 logistics run on partner coordination rather than a shared timeline, and dose readiness is reconstructed per shipment. A coordination view across CDMOs, transit and clinical sites is missing today.
Regulatory readiness 42 → 82
21 CFR Part 11, GAMP5 and Trial Review Committee submissions need a more direct lineage from source records to dossier. The escalating ABY-271 work makes that gap visible on a defined timeline.
Cybersecurity 38 → 78
Air-gapped legacy equipment and a widening clinical footprint create both access constraints and a larger attack surface. Zero-trust connectivity is described as the route through, not yet as the standing posture.
Process intelligence 28 → 72
Real-time KPI visibility from laboratory equipment is limited, with most analysis retrospective. The Solna lab work and the ABY-271 dosimetry work would both benefit from running rather than after-the-fact intelligence.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Affibody AB, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].